SAN DIEGO, CA--(Marketwired - April 11, 2016) - Nobilis Therapeutics, today announced that Dr. Daqing Ma, MD, PhD, FRCA, a Macintosh Professor of Anesthesia and the Head of Anesthesia Research at the Imperial College of London (ICL), has joined its Scientific Advisory Board.

Dr. Ma's research team was the first to discover Xenon's neuroprotective efficacy in animal models, as well as established a molecular mechanism for its therapeutic effects. These findings have served as the scientific foundations for numerous clinical trials, including work that Nobilis Therapeutics is currently engaging in. 

Dr. Vlad Bogin, Nobilis Therapeutics' CEO, stated: "Dr. Ma is a well-recognized opinion leader in the field of Xenon research, who has published extensively and has discovered a numbers of previously unknown therapeutic properties of this Noble gas. We are pleased that Dr. Ma has agreed to give us time out of his enormously busy schedule and are honored to have him join our team of advisers."

Dr. Ma commented: "As a result of my training and interests, I believe that Nobilis Therapeutics has embarked on a very promising and innovative strategy to treat neurodegenerative and psychiatric conditions using gas-based therapeutic approaches involving Xenon. I am convinced that the technology that is being developed by the Company would be enormously helpful in improving treatment outcomes and quality of life of millions of patients, and I hope that my knowledge and resources can assist Nobilis Therapeutics in making their approach successful."

Dr. Ma completed his MD in China and his PhD at the Imperial College of London, and is the recipient of 3 postdoctoral fellowships, including University College London, Duke University and ICL, where he and his co-workers were first to discover the neuroprotective properties of Xenon gas. He has more than 180 publications of original articles being published in high impact peer reviewed journals covering research fields of Anesthesiology, Pharmacology, Neuroscience, Neurology and Nephrology, and is a holder of two international patents. His main research interests are organoprotection, postoperative cognitive dysfunction, Cancer and Pain. Dr. Ma's research has been supported by the grants from MRC, Alzheimer's Society-Bupa Foundation, BJA/RCoA, AAGBI, Westminster Medical School Research Trust, Action Medical Research and SPARKS, UK and European Society of Anesthesiology, Brussels. He is a regularly invited reviewer for over 50 peer reviewed journals.

About Nobilis Therapeutics

Nobilis Therapeutics, LLC is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have exceptional safety profile proven by decades of clinical use. The Company has filed IP on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in treatment of over 500 patients for conditions ranging from panic attacks to substance abuse.